CD19 and B-cell non-Hodgkin lymphoma: Four of them (tisagenlecleucel (isa-cel), axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (lisa-cel), and brexucabtagene autoleucel (brexu-cel)) are directed against the Cluster of Differentiation 19 (CD19) antigen, a plasma membrane integral protein selectively expressed on B-cells’ surface, which controls B-lymphocytes’ differentiation and survival and, therefore, is an ideal target for the immunotherapy of B-cell lymphomas [7].